FDA-cleared profile

LungQ 4

Thirona BV · CT/CTA · FDA-cleared (510(k))

Authorized purpose: Quantitative support for thoracic CT interpretation and treatment planning, including emphysema burden, airway/lung segmentation, endobronchial valve assessment and estimated chronic perfusion defect.

Clinical role
Quantitative analysis and treatment-planning aid used with thoracic CT; clinicians review the source images and results.
Images and patients
CT/CTA · Chest/Lung
Key limitation
Keep in mind: The application is an adjunctive quantitative tool and does not replace clinician review. The public summary describes a command-line, no-GUI deployment, and local operators must verify input routing, supported CT protocols and interpretation workflow.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Quantitative support for thoracic CT interpretation and treatment planning, including emphysema burden, airway/lung segmentation, endobronchial valve assessment and estimated chronic perfusion defect.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Chest/Lung Input: DICOM thoracic CT datasets processed by a Docker image and standalone command-line application; the cleared configuration has no graphical user interface.
  • Who uses it?Intended users: Radiologists, pulmonologists and other qualified healthcare professionals interpreting thoracic CT.
  • What does the software produce?Output: 3D left/right lung, lobe, subsegment and airway segmentations; lung volume; density distributions and 15th-percentile density; LAA-950HU and LAA-910HU scores; fissure analysis; specified endobronchial implant count/analysis; and estimated chronic perfusion defect.
  • What is its most important limitation?Key limitation: The application is an adjunctive quantitative tool and does not replace clinician review. The public summary describes a command-line, no-GUI deployment, and local operators must verify input routing, supported CT protocols and interpretation workflow.

Clinical takeaway. Clinical role: Quantitative support for thoracic CT interpretation and treatment planning, including emphysema burden, airway/lung segmentation, endobronchial valve assessment and estimated chronic perfusion defect.

Evidence takeaway. Evidence from the reviewed source record: The FDA summary reports head-to-head agreement with LungQ v3 for volume, density and airway segmentation. In the endobronchial implant dataset, valve sensitivity was at least 95% and precision at least 90%. Chronic perfusion-defect analysis met prespecified agreement criteria against perfusion reference methods; no sample size was stated in the reviewed summary.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Quantitative support for thoracic CT interpretation and treatment planning, including emphysema burden, airway/lung segmentation, endobronchial valve assessment and estimated chronic perfusion defect.
  • Exact FDA submission
  • Checked 2026-09-07
Workflow role
Quantitative analysis and treatment-planning aid used with thoracic CT; clinicians review the source images and results.
  • Exact FDA submission
  • Checked 2026-09-07
Required input
DICOM thoracic CT datasets processed by a Docker image and standalone command-line application; the cleared configuration has no graphical user interface.
  • Exact FDA submission
  • Checked 2026-09-07
Output and clinician action
3D left/right lung, lobe, subsegment and airway segmentations; lung volume; density distributions and 15th-percentile density; LAA-950HU and LAA-910HU scores; fissure analysis; specified endobronchial implant count/analysis; and estimated chronic perfusion defect.
  • Exact FDA submission
  • Checked 2026-09-07
Care setting
Pulmonary and radiology services using thoracic CT, including evaluation for emphysema and endobronchial valve treatment.
  • Exact FDA submission
  • Checked 2026-09-07
Intended users
Radiologists, pulmonologists and other qualified healthcare professionals interpreting thoracic CT.
  • Exact FDA submission
  • Checked 2026-09-07
Limitations
The application is an adjunctive quantitative tool and does not replace clinician review. The public summary describes a command-line, no-GUI deployment, and local operators must verify input routing, supported CT protocols and interpretation workflow.
  • Exact FDA submission
  • Checked 2026-09-07
Evidence summary
The FDA summary reports head-to-head agreement with LungQ v3 for volume, density and airway segmentation. In the endobronchial implant dataset, valve sensitivity was at least 95% and precision at least 90%. Chronic perfusion-defect analysis met prespecified agreement criteria against perfusion reference methods; no sample size was stated in the reviewed summary.
  • Exact FDA submission
  • Checked 2026-09-07

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The FDA summary reports head-to-head agreement with LungQ v3 for volume, density and airway segmentation. In the endobronchial implant dataset, valve sensitivity was at least 95% and precision at least 90%. Chronic perfusion-defect analysis met prespecified agreement criteria against perfusion reference methods; no sample size was stated in the reviewed summary.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Reported sensitivity
>=95% for endobronchial valve detection in the FDA-described validation dataset
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07

This endpoint is specific to the described endobronchial implant dataset, not a general thoracic CT sensitivity claim.

Reported specificity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-07

The FDA summary reports precision for endobronchial valve detection, not a general exact-submission specificity endpoint.

Endobronchial valve detection sensitivity

0.95 proportion, minimum reported threshold

  • EndpointSensitivity
  • PopulationEndobronchial implant CT dataset with expert clinical truthers
  • Tested versionLungQ 4 configuration submitted in K250766

Endobronchial valve detection precision

0.9 proportion, minimum reported threshold

  • EndpointPrecision
  • PopulationEndobronchial implant CT dataset with expert clinical truthers
  • Tested versionLungQ 4 configuration submitted in K250766

LungQ 4 quantitative segmentation validation

  • DesignHead-to-head software validation against LungQ v3 described in the FDA 510(k) summary
  • PopulationThoracic CT datasets for lung, lobe, airway volume, density and segmentation analyses
  • Scopeexact submission
  • Tested versionLungQ 4 configuration submitted in K250766
  • IndependenceSponsor or vendor study

K250766

Acceptance criteria were met for the described analyses; the public summary does not provide one consolidated cohort size.

LungQ 4 endobronchial implant analysis validation

  • DesignMulticenter CT dataset with post-treatment studies and negative controls, interpreted against expert clinical truthers
  • PopulationPatients with endobronchial implants and negative controls
  • Scopeexact submission
  • Tested versionLungQ 4 configuration submitted in K250766
  • IndependenceSponsor or vendor study

K250766

FDA reports valve sensitivity >=95% and precision >=90%.

LungQ 4 chronic perfusion-defect analysis validation

  • DesignComparison with HRCT plus planar perfusion scintigraphy and HRCT plus SPECT-CT; pulmonologist treatment-planning assessment
  • PopulationThoracic CT cases evaluated against perfusion reference methods
  • Scopeexact submission
  • Tested versionLungQ 4 configuration submitted in K250766
  • IndependenceSponsor or vendor study

K250766

FDA reports ICC >0.75, bias <5% and limits of agreement from -10% to 10%; cohort size was not stated in the reviewed summary.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-07

The downloaded exact-ID recall packet contained zero records; this limited result does not establish absence of recall or safety information.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: DICOM thoracic CT datasets processed by a Docker image and standalone command-line application; the cleared configuration has no graphical user interface.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-07 · FDA 510(k) K250766: LungQ 4

  2. Routing

    Source context, not route validation: Receives DICOM thoracic CT datasets and returns derived analyses for use with the source study; the cleared submission does not establish a buyer's specific PACS, orchestration or reporting configuration.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-07 · FDA 510(k) K250766: LungQ 4

  3. AI processing

    Source context, not route validation: Docker image and standalone command-line software without a GUI.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-07 · FDA 510(k) K250766: LungQ 4

  4. Returned objects

    Source context, not route validation: 3D left/right lung, lobe, subsegment and airway segmentations; lung volume; density distributions and 15th-percentile density; LAA-950HU and LAA-910HU scores; fissure analysis; specified endobronchial implant count/analysis; and estimated chronic perfusion defect.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-07 · FDA 510(k) K250766: LungQ 4

  5. Viewer/worklist/report

    Unresolved route: 3D left/right lung, lobe, subsegment and airway segmentations; lung volume; density distributions and 15th-percentile density; LAA-950HU and LAA-910HU scores; fissure analysis; specified endobronchial implant count/analysis; and estimated chronic perfusion defect.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-07 · FDA 510(k) K250766: LungQ 4

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
Docker image and standalone command-line software without a GUI.
  • Exact FDA submission
  • Checked 2026-09-07
Integration
Receives DICOM thoracic CT datasets and returns derived analyses for use with the source study; the cleared submission does not establish a buyer's specific PACS, orchestration or reporting configuration.
  • Exact FDA submission
  • Checked 2026-09-07
Security
Thirona's quality and compliance page states its product development is grounded in a certified quality management system (ISO 13485) and lists ISO 27001 and EU GDPR under its information security and data governance standards, applied to its lung image analysis software.
  • Vendor-wide
  • Checked 2026-10-27

Vendor statement; the certificate was not read. Page is company-scoped for Thirona's lung image analysis software including LungQ. Exact-release scope is not established. Applied only to Thirona BV entries; 'Thirona Corporation' (K173821) is an unbridged entity variant.

Containerized command-line deployment

The cleared software is distributed as a Docker image and standalone command-line application without a GUI.

exact submission · checked 2026-09-07

Versioned implementation documentation

Thirona maintains an official manuals and configuration-files portal for LungQ products; the landing page does not establish the exact K250766 package, support contract or local integration terms.

product family · checked 2026-09-07
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K250766
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Anatomy
Chest/Lung
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-10-02
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-07Last searched
23Fields reviewed
11Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

Stored candidate metadata was screened; no PubMed or trial IDs were returned for this submission. This is not a full-paper review. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor press release, vendor documentation portal, stored candidate metadata, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-07 - Exact FDA submission

    No public price or quote for the K250766 configuration was reviewed.

  • Pricing model: Not verified - checked 2026-09-07 - Exact FDA submission

    License, compute, support and implementation terms were not established.

  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission

    Bounded web search on 2026-10-26 (query: "Thirona LungQ reimbursement CPT"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. No result was a vendor or payer page naming this product with coding or payment; any results were general billing guidance. This records what was found, not that none exists.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-10-27 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-10-27 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

9 sources - 3 history items

Source ledger

  1. FDA 510(k) K250766: LungQ 4

    U.S. Food and Drug Administration - Accessed 2026-09-07

    Scope: identity, purpose, clinicalUse, modality, anatomy, workflowRole, intendedUsers, careSetting, input, output, limitations, integration, deployment, evidenceMetrics, evidenceStudies

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. LungQ 4 model card (K250766)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. Thirona Receives FDA Clearance for LungQ 4 Software

    Thirona - Accessed 2026-09-06

    Scope: productFamilyContext, clinicalUse, implementationCapabilities

  8. Download Manuals & Configuration Files

    Thirona - Accessed 2026-09-07

    Scope: implementationCapabilities

  9. Thirona: Quality & Compliance

    Thirona - Accessed 2026-10-27

    Scope: security

Research history

  1. K250766 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K251474

Median LCS (internal name) / eyonis LCS (trade name) (1.0)

Median Technologies

eyonis LCS is a concurrent-reading aid for radiologists that detects, localizes, and characterizes 4-30 mm solid and part-solid pulmonary nodules on low-dose chest CT images for high-risk lung cancer screening patients; it provides nodule measurements and malignancy scores and does not replace physician judgment.

Modality
CT/CTA
Anatomy
Chest/Lung
Decision
2026-02-06
FDA-cleared K232412

LungQ v3.0.0

Thirona BV

The Thirona LungQ software provides reproducible CT values for pulmonary tissue which is essential for providing quantitative support for diagnosis and follow up examination. The LungQ software can be used to support physician in the diagnosis and documentation of pulmonary tissues images (e.g. abnormalities) from CT thoracic datasets. Three-D segmentation and isolation of sub-compartments, volumetric analysis, density evaluations, fissure evaluation, and reporting tools are provided.

Modality
CT/CTA
Anatomy
Chest/Lung
Decision
2024-01-08
FDA-cleared K213713

AI-Rad Companion (Pulmonary)

Siemens Healthcare GmBh

AI-Rad Companion (Pulmonary) is image processing software that provides quantitative and qualitative analysis from previously acquired Computed Tomography DICOM images to support radiologists and physicians from emergency medicine, specialty care, urgent care, and general practice in the evaluation and assessment of disease of the lungs. It provides the following functionality: Segmentation and measurements of complete lung and lung lobes Identification of areas with lower Hounsfield values in comparison to a predefined threshold for complete lung and lung lobes Providing an interface to external Medical Device syngo.CT Lung CAD Segmentation and measurements of solid lung nodules. Dedication of found lung nodules to corresponding lung lobe. Correlation of segmented lung nodules of current scan with known priors and quantitative assessment of changes of the correlated data. Identification of areas with elevated Hounsfield values, where areas with elevated versus high opacities are distinguished. The software has been validated for data from Siemens Healthineers (filtered back projection and iterative reconstruction),GE Healthcare (filtered back projection reconstruction), and Philips (filtered back projection reconstruction).Only DI COM images of adult patients are considered to be valid input.

Modality
CT/CTA
Anatomy
Chest/Lung
Decision
2022-08-11

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history